NasdaqGM:EOLSPharmaceuticals
Evolus (EOLS) Nears Breakeven In Q4 EPS Challenging Prolonged Loss Narratives
Evolus (EOLS) has wrapped up FY 2025 with fourth quarter revenue of US$90.3 million and basic EPS close to breakeven at about US$0.00, against trailing twelve month revenue of US$297.2 million and a loss of US$51.6 million on that same basis. Over recent quarters, the company has seen quarterly revenue move from US$78.9 million in Q4 2024 to US$68.5 million, US$69.4 million, US$69.0 million and then US$90.3 million in Q4 2025. Basic EPS ranged from a loss of about US$0.30 in Q1 2025 to...